Acquisition Tease Market interest from QOL Medical LLC has surfaced with a potential cash acquisition at $11 per share, indicating a strategic buyer landscape and potential channel changes that could open partnership or distribution opportunities for GI-focused products and nasal spray therapies.

GIMOTI Focus GIMOTI (metoclopramide) nasal spray is a core asset with granted patent protections. This creates a licensing, co-development, or distribution partnership opportunity with companies serving gastroenterology, neurology, and post-surgical care where nausea, gastroparesis, and GI motility are key concerns.

Patent Momentum Recent USPTO patent activity, including a Notice of Allowance for use of GIMOTI in gastroparesis, signals defensible market advantage and potential for exclusive regional deals, pricing collaborations, or milestone-driven partnerships with larger pharma players.

Clinical Visibility Evoke Pharma’s engagement at major GI conferences and data presentations positions the company as a research-driven partner for co-promote or co-develop opportunities around GI disorders, gastroparesis, and dysmotility therapies.

Growth Readiness Moderate revenue scale and established leadership with board-level additions suggest readiness for channel expansion, OEM collaborations, and specialty distribution agreements with healthcare providers, DSA networks, or specialty pharmacies targeting GI patients.